Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - desogestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; potato starch - oral contraception.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

organon malaysia sdn. bhd. - desogestrel; ethinyloestradiol -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

organon malaysia sdn. bhd. - ethinyloestradiol; desogestrel -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

organon malaysia sdn. bhd. - tibolone -

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - neurology - an instrument for monitoring the neuromuscular transmission during surgery by means of acceleromography. the tof-watch can also be used as a peripheral nerve stimulator. moreover, it can be used to localize nerves for loco-regional anaesthesia. tof-watch is only to be operated by trained medical personnel.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - losartan potassium - tablets - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar 50 mg is indicated for the treatment of hypertensionheart failure: ocsaar 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to ocsaar 50 mg is not recommended.renal protection in type-2 diabetic patients with proteinuria: ocsaar 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar 50 mg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.the benefit of ocsaar 50 mg on the primary deposite endpoint was largely driven by reduction in the risk of stroke.

Singapore - English - HSA (Health Sciences Authority)

organon singapore pte. ltd. - hydrochlorothiazide; losartan potassium - tablet, film coated - 12.50 mg - hydrochlorothiazide 12.50 mg; losartan potassium 100.0mg

Singapore - English - HSA (Health Sciences Authority)

organon singapore pte. ltd. - losartan potassium - tablet, coated - 100 mg - losartan potassium 100 mg

Singapore - English - HSA (Health Sciences Authority)

organon singapore pte. ltd. - losartan potassium - tablet, coated - 50 mg - losartan potassium 50 mg

Singapore - English - HSA (Health Sciences Authority)

organon singapore pte. ltd. - desloratadine, micronized - solution - 0.5 mg/ml - desloratadine, micronized 0.5 mg/ml